NeurologyLive® Friday 5 — January 12, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 12, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: A Neurological Perspective on Lessons from the COVID-19 Pandemic in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

The neuroimmunologist at Clínica Alemana de Santiago and head of the University Center for Multiple Sclerosis at Ramos Mejía Hospital discussed Latin American efforts to understand neuromyelitis optica spectrum disorder during the COVID-19 pandemic. [WATCH TIME: 5 minutes]

A Neurological Perspective on Lessons from the COVID-19 Pandemic in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

2: Exploring Epstein Barr Virus Connection in Multiple Sclerosis Research: J. William Lindsey, MD

The professor in the department of neurology with McGovern Medical School at UTHealth Houston talked about findings from a recent study that investigated T cell specificity in the spinal fluid of patients with multiple sclerosis. [WATCH TIME: 10 minutes]

Exploring Epstein Barr Virus Connection in Multiple Sclerosis Research: J. William Lindsey, MD

3: NeurologyLive Insights: Red Flag Symptoms of CIDP

In episode 4 of the "Are You Recognizing CIDP? Changing the Course With Evolving Treatment Strategies" video series, Richard Lewis, MD, professor of neurology at Cedars-Sinai Medical Center, reviews the red flag symptoms of CIPD that should prompt a referral your patient.

Red Flag Symptoms of CIDP

4: NeuroVoices: Adam Mecca, MD, PhD, on mGlurR5 Modulator ALX-001 as Potential Treatment for Alzheimer Disease

In this week's NeuroVoices Q&A, the associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine provided commentary on positive phase 1 findings assessing ALX-001, a highly selective agent in development for neurodegenerative diseases.

NeuroVoices: Adam Mecca, MD, PhD, on mGlurR5 Modulator ALX-001 as Potential Treatment for Alzheimer Disease

5: MEDCast: Paradigm Shift In Parkinson’s Disease Diagnosis

In this episode of the "Paradigm Shift in Parkinson’s Disease Diagnosis" video series, neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.

Paradigm Shift In Parkinson’s Disease Diagnosis
Related Videos
 Bruce Cree, MD, PhD, MAS, FAAN
Video 3 - 5 KOLs are featured in "Transitions of Care: Moving Spinal Muscular Atrophy Patients from Pediatric/Adolescent Care to Adult Clinics"
Video 3 - 5 KOLs are featured in "Presentation of Adult Spinal Muscular Atrophy in Clinics"
Fawad Khan, MD, FACNS
Valerie J. Block, PT, DPTSc
Sanjay R. Patel, MD, MS
© 2024 MJH Life Sciences

All rights reserved.